Resumen

El propósito de este estudio es conocer los efectos de tres medicamentos en investigación (encorafenib, binimetinib y pembrolizumab) administrados en combinación para el tratamiento del melanoma que: * es avanzado o metastásico (se ha diseminado a otras partes del cuerpo); * tiene un cierto tipo de gen anormal llamado "BRAF"; y * no ha recibido tratamiento previo. Todos los participantes en este estudio recibirán pembrolizumab en la clínica del estudio una vez cada 3 semanas como infusión intravenosa (IV) (administrada directamente en una vena). Además, la mitad de los participantes tomarán encorafenib y binimetinib por vía oral (por boca) en su domicilio todos los días. Los participantes pueden recibir pembrolizumab hasta por dos años. Aquellos participantes que tomen encorafenib y binimetinib pueden continuar hasta que su melanoma deje de responder. El equipo del estudio monitoreará la evolución de cada participante con el tratamiento del estudio durante visitas regulares en la clínica del estudio.

Descripción detallada

Este estudio comparará la eficacia, seguridad y tolerabilidad de encorafenib y binimetinib más pembrolizumab (brazo triple) versus placebo más pembrolizumab (brazo control) en participantes con melanoma metastásico o localmente avanzado irresecable con mutación BRAF V600E/K positiva. El estudio tendrá una fase de introducción de seguridad abierta (SLI) para determinar la seguridad, la dosis recomendada para la fase 3 (RP3D) y la farmacocinética (PK) de la terapia combinada de encorafenib y binimetinib más pembrolizumab antes del inicio de la parte aleatorizada de fase 3 del estudio. Se explorarán en paralelo dos niveles de dosis de encorafenib en combinación con binimetinib más pembrolizumab. Se inscribirá un mínimo de 12 participantes evaluables por nivel de dosis. Durante la parte aleatorizada doble ciego de fase 3 del estudio, aproximadamente 216 participantes elegibles serán aleatorizados en una proporción 1:1 al brazo triple (a la RP3D determinada en la SLI) o al brazo control (aproximadamente 108 participantes por brazo). La aleatorización se estratificará por terapia adyuvante sistémica previa y estadio de la enfermedad según AJCC (8.ª edición).

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Male or female participants ≥ 18 years at the time of informed consent.
Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition.
Presence of at least 1 measurable lesion as detected by radiological and/or photographic methods according to RECIST v1.1.
ECOG performance status 0 or 1.
Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked \[European conformity\] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory.
Submission of adequate tumor tissue (archival or newly obtained; block or slides to the sponsor central laboratory(ies) during the screening period and prior to enrollment (SLI)/randomization (Phase 3).
Have not received prior first-line systemic therapy for metastatic or unresectable locally advanced melanoma.
Adequate bone marrow function, hepatic and renal function.
Capable of giving signed informed consent.

Criterios de exclusión

Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study (including, but not limited to, a participant who is rapidly progressing or has clinically significant tumor related symptoms, in the judgment of the investigator).
Mucosal or ocular melanoma.
Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
Unable to swallow, retain, and absorb oral medications.
Impairment of GI function or disease which may significantly alter the absorption of oral study intervention (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, including malabsorption syndrome secondary to prior GI surgery).
Clinically significant cardiovascular diseases,
History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to enrollment (SLI)/randomization (Phase 3). Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive) deep vein thrombosis or pulmonary emboli.
History or current evidence of RVO or current risk factors for RVO (eg, uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
Concurrent neuromuscular disorder that is associated with the potential of elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
Current noninfectious pneumonitis or history of noninfectious pneumonitis requiring steroids, or history of radiation pnuemonitis
Evidence of HBV or HCV infection.
Known history of a positive test for HIV or known AIDS.
Any active infection requiring systemic therapeutic treatment within 2 weeks prior to enrollment (SLI)/ randomization (Phase 3).
Participants with prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases.
Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason ≤ 6 prostate cancer. Participants with a history of other curatively treated cancers must be reviewed with the sponsor or designee prior to entering the study.
Participants who previously received and subsequently discontinued encorafenib and/or binimetinib and/or anti-PD-1/-L1 due to severe toxicity.
For participants in the SLI only: Current use or anticipated need for food or drugs that are known moderate or strong CYP3A4 inhibitors during screening and through the DLT-evaluation period
Participant has not recovered to Grade ≤ 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before enrollment (SLI)/ randomization (Phase 3).
Receipt of protocol defined medications or treatments outside of required intervals before enrollment (SLI)/randomization (Phase 3):
Previous administration with an investigational drug ≤ 6 months prior to enrollment (SLI)/randomization (Phase 3).
Known sensitivity or contraindication to any component of study intervention (encorafenib, binimetinib and pembrolizumab), or their excipients.
Pregnant, confirmed by a positive β-hCG laboratory test result, or is breastfeeding (lactating).
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Estudio de fase 3, aleatorizado, doble ciego, de encorafenib y binimetinib más pembrolizumab versus placebo más pembrolizumab en participantes con melanoma metastásico o localmente avanzado irresecable con mutación BRAF V600E/K positiva

Resumen

Descripción detallada

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Encorafenib

Binimetinib

Pembrolizumab

Ubicaciones

Instituto Alexander Fleming

Clinica Viedma S. A

Patrocinadores